Heart Failure – Current Treatment – Detailed, Expanded Analysis: Chronic Heart Failure – Preserved Ejection Fraction – Treatment Algorithms – Claims Data Analysis (US)
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology has improved, pharmacological treatments with proven outcomes benefits in HFpEF have been elusive. Indeed, agents with proven efficacy treating heart failure with reduced ejection fraction (HFrEF), such as Novartis’s Entresto, have consistently fallen short in HFpEF studies. Thus, drug treatment of HFpEF focuses on the management of comorbidities, and first-line treatment typically consists of RAAS inhibitors, beta blockers, and diuretics. Unlike in HFrEF patients, calcium channel blockers can be used in this subpopulation. This analysis provides insight into U.S. prescribing patterns for HFpEF.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFpEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFpEF patients?
- How has Entresto been integrated into the treatment algorithm, and what is its source of business?
- What percentage of HFpEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFpEF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Merck, Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, BiDil, Corlanor, Entresto
Table of contents
- Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Preserved Ejection Fraction - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Chronic Heart Failure with Preserved Ejection Fraction US March 2022
- Treatment Algorithms CDA Chronic Heart Failure with Preserved Ejection Fraction US 2022 Dashboard
Dwaipayan Chatterjee, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports focusing on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.